Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
NCT ID: NCT01125722
Last Updated: 2012-12-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
74 participants
INTERVENTIONAL
2010-04-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Research has shown that a process called neuromodulation of the nerves controlling the bladder can overcome this communication problem. In patients who have symptoms caused by the communication problem, neuromodulation has been clinically proven to eliminate or significantly reduce those symptoms. While neuromodulation has been previously achieved by implanting an electrode near the sacral nerve in the spine, the new concept under investigation within this protocol is believed to achieve a similar effect from adhesive electrodes placed on the skin over spinal nerves in the lower back.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Investigator Placement Group
Non-invasive neurostimulation device
Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
Subject Placement Group
Non-invasive neurostimulation device
Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-invasive neurostimulation device
Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
Non-invasive neurostimulation device
Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and Females, at least 18 years of age
* Documented symptoms of idiopathic overactive bladder for at least 6 months
* Failure on primary OAB treatment, such as behavior modification or fluid/diet management, AND at least one (1) anti-cholinergic drug
* An average of one (1) or more urgency (urinary) incontinence episodes per 24-hours, confirmed by the 3-day baseline voiding diary, with a maximum of 12 urgency (urinary) incontinence episodes per 24-hours
* An average of eight (8) or more voids per 24-hours, confirmed by the 3-day baseline voiding diary
* Demonstrated ability to adequately complete the 3-day baseline voiding diary
* Willing and capable of understanding and complying with all requirements of the protocol
* Signed Informed Consent to participate in the study after full discussion of the research nature of the treatment and its risks and benefits.
Exclusion Criteria
* Urinary retention
* Clinically significant bladder outlet obstruction
* Morbidly obese, defined as having BMI \> 40 kg/m2
* Stress predominant mixed urinary incontinence
* Neurological disease affecting urinary bladder function, including but not limited to Parkinson's disease, multiple sclerosis, stroke, spinal cord injury.
* History of epilepsy
* Pelvic surgery (such as sub-urethral sling, pelvic floor repair) within the past 6 months
* Intravesical or urethral sphincter Botulinum Toxin Type A injections within the past 12 months
* Failure of previous neuromodulation therapy for overactive bladder
* Percutaneous Tibial Nerve Stimulation (PTNS) therapy for overactive bladder within the past 6 months
* Any clinically significant congenital or acquired disorder of the urogenital tract (including denovo OAB following sub-urethral sling)
* Vaginal prolapse greater than Stage II in the anterior compartment of the vagina using International Continence Society (ICS) Pelvic Organ Prolapse Quantification (POPQ) criteria.
* Prior peri-urethral or transurethral bulking agent injections for bladder problems within the past 12 months.
* History of pelvic radiation therapy
* Any skin conditions affecting treatment or assessment of the treatment sites
* History of lower back surgery or injury that could impact placement of the patch, or where underlying scar tissue or nerve damage may impact treatment.
* Unable to operate the device remote control.
* Lacking dexterity to properly utilize the components of the device system.
* Presence of an implanted electro-medical device (e.g. pacemaker, defibrillator, InterStim®, etc.),
* Any metallic implant in the back.
* Pregnant, nursing, suspected to be pregnant (by urine pregnancy method), or plans to become pregnant during the course of the study.
* History of dementia or Alzheimer's disease.
* Known latex allergies
* Uncontrolled diabetes and/or diabetes with peripheral neuropathy.
* Transurethral instrumentation within the preceding month.
* Scheduled for any of the following during the course of the study: Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), X-ray, Ultrasound, or Radiotherapy (targeting full body or back region)
* Recurrent Urinary Tract Infections (\>3 UTI's in the past year)
* Clean catch Urinalysis results \>10wbc/hpf
* History of or current lower tract genitourinary malignancies
* Any clinically significant systemic disease or condition that in the opinion of the Investigator would make the patient unsuitable for the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novella Clinical
OTHER
Data & Inference, Inc.
INDUSTRY
Ethicon Endo-Surgery
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ashwani Monga, BM BS, MRCOG
Role: PRINCIPAL_INVESTIGATOR
Princess Anne Hospital, Southampton, UK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Faculty Associates, The George Washington University
Washington D.C., District of Columbia, United States
William Beaumont Hospital - Department of Urology
Royal Oak, Michigan, United States
AdvanceMed Research
Lawrenceville, New Jersey, United States
Delaware Valley Urology, LLC
Mount Laurel, New Jersey, United States
McKay Urology
Charlotte, North Carolina, United States
Alliance Urology Specialists, P.A.
Greensboro, North Carolina, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Wheaton Franciscan Medical Group, Milwaukee Urogynecology
Wauwatosa, Wisconsin, United States
Danderyd University Hospital
Stockholm, , Sweden
Princess Anne Hospital
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CI-10-0001
Identifier Type: -
Identifier Source: org_study_id